Tag Archives: Ricolinostat

Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments

Regenacy Pharmaceuticals, a biotech formed as part of Celgene’s acquisition of Acetylon Pharmaceuticals in late 2016, has raised $30 million in Series A financing to move its lead program into a Phase 2 proof-of-concept trial this year. The Waltham, MA-based company is developing treatments to address the underlying cause of peripheral neuropathies—a form of nerve […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments

Acetylon Crafts New Buyout Deal With Celgene, Spins Out Startup Regenacy

[Updated, 12/5/16, see below] Earlier this year, Celgene passed on an exclusive option to buy Acetylon Pharmaceuticals. But surprisingly, the two companies have come up with a new deal instead. Celgene agreed Friday to acquire just a portion of the assets of the Boston company, which will spin the rest of its assets into a […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , | Comments Off on Acetylon Crafts New Buyout Deal With Celgene, Spins Out Startup Regenacy

Celgene Passes on Acetylon as Another Option-to-Buy Deal Flames Out

The option-to-buy deal, in biotech, is a way to hedge a bet. A big firm will pay a fee for the right to acquire a smaller company later on, with the big bucks coming only if the acquisition is triggered. An option isn’t a guarantee, however; a big company can always pass on a buyout, […]

Posted in Boston, Boston blog main, Boston top stories, Detroit blog main, National blog main, National top stories, New York blog main, New York top stories, Seattle blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Celgene Passes on Acetylon as Another Option-to-Buy Deal Flames Out